Head to Head Review: Rezolute (NASDAQ:RZLT) versus Oculis (NASDAQ:OCS)

Rezolute (NASDAQ:RZLT) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.

Earnings & Valuation

This table compares Rezolute and Oculis”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41 million	($0.93)	-3.35
Oculis	$780,000.00	1,912.54	-$97.43 million	($2.52)	-11.30

Rezolute has higher earnings, but lower revenue than Oculis. Oculis is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Rezolute and Oculis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-62.82%	-57.08%
Oculis	-12,915.42%	-80.82%	-61.18%

Insider & Institutional Ownership

83.0% of Rezolute shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 14.8% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations for Rezolute and Oculis, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1	5	6	0	2.42
Oculis	1	0	8	0	2.78

Rezolute presently has a consensus target price of $8.67, suggesting a potential upside of 177.78%. Oculis has a consensus target price of $41.50, suggesting a potential upside of 45.72%. Given Rezolute’s higher possible upside, equities research analysts plainly believe Rezolute is more favorable than Oculis.

Risk & Volatility

Rezolute has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Oculis has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.

Summary

Rezolute beats Oculis on 10 of the 13 factors compared between the two stocks.

About Rezolute

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.